Dr. Patt on the Role of Sacituzumab Govitecan in TNBC

Debra Patt, MD, PhD, MBA, ​breast medical oncologist​, vice president of Texas Oncology, highlight​s the role of sacituzumab govitecan-hziy (Trodelvy) in triple-negative breast cancer (TNBC).

 Sacituzumab govitecan, a​n antibody-drug conjugate, is a standard treatment option for patients with ​metastatic TNBC. Other ​breast cancer therapies, such as immunotherapy, can only be administered to a select group of patients ​with TNBC, Patt says.

As more targeted therapies enter the TNBC ​paradigm, it will be important to glean a better understanding of which patients will derive the most ​benefit from sacituzumab govitecan​. However, ​as it stands, sacituzumab govitecan can be used more broadly for patients with TNBC compared with other therapies, Patt concludes.